Faezeh Malekzadeh
1 , Shaghayegh Kermaninezhad
2 , Amin Reza Nikpoor
3 , Mohammad Ali Vahidipour
2* , Ali Salimi Asl
2* 1 Student Research Committee, Faculty of Para-Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
2 Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
3 Department of Immunology, Faculty of Medicine, Hormozgan University of Medical Science, Bandar Abbas, Iran.
*Corresponding Authors: *Correspondence to Mohammad Ali Vahidipour, Ali Salimi Asl, Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Tel:+989356911283; Email: , Email:
mali_vahidipour@ yahoo.com; *Correspondence to Mohammad Ali Vahidipour, Ali Salimi Asl, Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Tel:+989307424323; Email: , Email:
shervin7717@gmail. com
Abstract
Coronavirus disease 2019 (COVID-19) is a new pathogen which has become an uncontrollable pandemic. On the other hand, the humoral immune system, as a defensive line, protects the body by producing antibodies. Immunoglobulin M (IgM) and G (IgG) are considered as the most important antibodies that are produced by the immune system of the host. Previous evaluations on the production of IgM and IgG antibodies by patients suffering from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection specifies that IgM is an acute phase antibody and increases on the first days of infection. Then, as the chronic phase begins, the level of the IgM decreases and switches to the production of IgG. In addition, the durability of the IgG antibody shows the duration of the immunity against COVID-19. Thus, the present review article focused on the antibody production mechanism in studies conducted on COVID-19 patients, the protection role of antibodies, and their stability.